xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns="http://www.w3.org/TR/REC-html40">
http://www.nytimes.com/2001/11/05/business/05VACC.html
November 5, 2001
THE VACCINE
U.S. Looks for More Vaccine Sources
By KEITH BRADSHER with MICHAEL WINES
ASHINGTON,
Nov. 4 The United States has begun looking for scarce anthrax vaccine
overseas as a precaution in case lingering production problems cannot be
resolved at an American vaccine factory.
Britain has already provided samples of its vaccines for testing, and more
samples are being sought from other countries, federal health officials said.
The Food and Drug Administration does not accept medicines produced overseas
until they have been extensively tested in the United States, which sometimes
takes years.
"We have not done the tests, and that's one of the problems,"
Tommy G. Thompson, the secretary of health and human services, told reporters
on Friday. A federal drug official said the agency was trying to work quickly
on many bioterrorism issues, including anthrax vaccines, but without
sacrificing safety.
The F.D.A. required the only American factory making anthrax vaccine to shut
down in December 1999 after an inspection found 30 violations involving safety,
consistency, record-keeping and sterility. Mr. Thompson predicted two weeks ago
that the factory, in Lansing, Mich., owned by the BioPort Corporation, would
pass inspection and resume shipments by Thanksgiving.
But a federal official said this weekend that the factory might not be ready
until the end of November or early December. BioPort declined to provide a
timetable.
In addition to the United States, three countries are known to produce
anthrax vaccine for humans: Britain, China and Russia. At least a dozen
countries, including the United States, manufacture vaccines for livestock;
medical experts say the veterinary vaccines are very similar to the Russian
vaccines for people.
Many doctors say veterinary vaccines could be used to treat people in the
United States in an emergency if millions of Americans were exposed to
anthrax and all other supplies of antibiotics and vaccine ran out. But
veterinary vaccines may carry more serious side effects than the American
vaccine for people, they warn.
In Britain, a government laboratory known as the Center for Applied
Microbiology and Research makes a vaccine that is administered each year to
about 1,000 people, most of them veterinarians, farmers, tanners and others who
may encounter anthrax at work.
Dr. Philip Luton, a spokesman for the British laboratory, declined to
discuss the center's production capacity or stockpiles. But vaccine samples
have been sent to American health officials for testing, he said.
The British vaccine is similar to the American vaccine. Neither uses live
anthrax spores or bacteria. Instead, toxins excreted by anthrax bacteria are
filtered from a bacterial culture. Tiny quantities of these toxins are mixed
with a fluid and injected so the inoculated person will develop antibodies to
the toxins. British and American vaccines use slightly different strains of
bacteria and are mixed with different fluids.
China has also developed a vaccine that uses filtered toxins, but less is
known about it.
Russia uses an older vaccine technology, inoculating people with live spores
of a weakened strain of anthrax. The vaccine was developed for livestock in the
late 1930's and came to be used for people, said Dr. Veniamin L. Cherkassky,
one of Russia's leading experts on anthrax.
Russia produces large quantities of the vaccine, inoculating 60,000
livestock industry workers for the first time each year and administering an
additional 100,000 booster shots annually, Dr. Cherkassky said. The Russian
vaccine is very strong, requiring a single dose, compared with four doses for the
British vaccine and six doses over two years for the American vaccine.
Dr. Cherkassky asserted that the Russian vaccine was safe because the spores
came from the weakened strain. "This vaccine does not give any reactions
it cannot give any reactions," he said. "There's nothing in it that
can give reactions."
Six American experts on anthrax vaccines said the Russian vaccine was
probably even more effective than the American vaccine in preventing the
recipient from falling ill with anthrax. But all six said the Russian vaccine
had more serious side effects.
Dr. Martin E. Hugh-Jones, an anthrax expert at Louisiana State University,
has studied Soviet-era medical records for 60,000 people in Sverdlovsk who were
inoculated in 1979 immediately after a leak from a nearby anthrax weapons
factory. The records showed a dozen cases of permanent neurological damage from
the vaccines, he said. The American and British vaccines carry no such risk, he
said, because they do not use live spores.
The Russian vaccine was probably painful, too, because many of the people
inoculated skipped subsequent prescribed doses, Dr. Hugh- Jones added.
Dr. Cherkassky said no one in Sverdlovsk had experienced a bad reaction to
the vaccine.
In the United States, no public officials have suggested mass immunizations
for the general public because they think that the risk of a mass anthrax
infection is low. The government is making plans to vaccinate 800 laboratory
workers, and there have also been proposals to vaccinate police officers, firefighters
and workers who decontaminate areas with anthrax.
Mr. Thompson has sought to reassure the public about anthrax vaccine, saying
on Friday that there was a stockpile of 5.4 million doses. But many of those
doses were recently produced by BioPort at the factory that the federal drug
agency closed. Representative Christopher Shays, a Connecticut Republican who
has led hearings on the vaccine's safety, said that fewer than 20,000 of the
doses in the stockpile were clearly safe.
The side effects of the American vaccine have been controversial, even
though they are not as serious as those from the Russian vaccine. The American
vaccine can cause redness and itching at the site of the injection and
sometimes flulike illnesses. Hospitalization is necessary for about one out of
each 200,000 people who get the vaccine, according to the Defense Department,
which inoculates soldiers going to high-risk regions like the Persian Gulf and
South Korea.
Several hundred people have quit the military in the last four years to
avoid receiving the injections. The F.D.A. has responded by saying the vaccine
is safe.
ALL INFORMATION, DATA,
AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR
OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING
MEDICAL OR LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN
IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN
CONSULTATION WITH YOUR HEALTH CARE PROVIDER.